EUVIMEDEUVIMED entdecken
Crossref

T-cell hitchhiking nanodrug activates the cGAS-STING signaling pathway for enhanced cancer immunotherapy

Qi Chen, Qiaoyun Zhang, Lizhen He, Meijin Yang, Heting Wang, Minzhao Lin, Bo Li, Gengjia Chen, Yong Wang, Tianfeng Chen, Xintao Shuai

Acta Biomaterialia · 2025

DOI: 10.1016/j.actbio.2025.10.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Qi Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Signal Transduction, Immunotherapy, Membrane Proteins, Nucleotidyltransferases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Guangdong Provincial Natural Science Foundation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the clinical success of immune checkpoint blockade (ICB) in cancer therapy, its efficacy against "cold" tumors like triple-negative breast cancer (TNBC) remains limited due to low immunogenicity and an immunosuppressive microenvironment. Emerging evidence suggests activating the cGAS-STING pathway to enhance antigen presentation is an effective strategy to turn TNBC from "cold" to "hot". Herein, we developed a nanodrug MnO@PPC-aPD-1 that incorporates MnO nanoparticles and anti-PD-1 antibodies (aPD-1) to overcome these limitations. The MnO@PPC-aPD-1 exploits T cell homing through surface-conjugated aPD-1 for tumor-specific delivery. Upon reaching the acidic tumor microenvironment (TME), the system releases aPD-1 to block immune checkpoints while simultaneously activating the cGAS-STING pathway in both antigen presenting cells and tumor cells via MnO@PPC. This dual action not only enhances antigen presentation but also suppresses immunosuppressive signals including ENPP1, NLRC3, and non-canonical NF-κB, effectively converting "cold" tumors to "hot". The treatment establishes a positive feedback loop by recruiting and activating tumor-infiltrating T cells, while generating memory T cells to prevent metastasis and recurrence. Our findings provide mechanistic insights into tumor immunogenicity modulation and demonstrate a promising approach for enhancing ICB efficacy in poorly immunogenic cancers. STATEMENT OF SIGNIFICANCE: Inadequate immune activation and lack of specific targets hinder effective immunotherapy for triple-negative breast cancer (TNBC). Here, we developed a tumor-agnostic delivery system-a T cell-hitchhiking nanodrug (MnO@PPC-aPD-1). This system leverages T cell homing via surface-conjugated aPD-1 for tumor-specific delivery, responding to the mildly acidic tumor microenvironment to release aPD-1 for checkpoint blockade. Concurrently, MnO@PPC activates the cGAS-STING pathway in both antigen-presenting cells and tumor cells. This dual mechanism not only enhances antigen presentation but also suppresses immunosuppressive signals (including ENPP1, NLRC3, and non-canonical NF-κB), effectively converting "cold" tumors to "hot." The therapy establishes a self-reinforcing cycle by recruiting and activating tumor-infiltrating T cells while generating memory T cells to prevent metastasis and recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionImmunotherapyMembrane ProteinsNucleotidyltransferasesT-LymphocytesTriple Negative Breast NeoplasmsNanoparticlesHumansAnimalsFemaleCell Line, TumorMiceTumor MicroenvironmentSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Stichwörter der Autor:innen

Dual-responsive nanomedicineImmunotherapyResponsive releaseTumor-specific deliverycGAS-STING

Substanzen

Membrane ProteinsNucleotidyltransferasesSTING1 protein, humanSTING ProteincGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Autor:innen und Institutionen

  • Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • College of Chemistry and Materials Science, Jinan University, Guangzhou 510632, China.
  • Department of Oncology, The First Affiliated Hospital, Jinan University, Guangzhou 510632, China.
  • Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical Uni…
  • Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
  • College of Chemistry and Materials Science, Jinan University, Guangzhou 510632, China. Electronic address: wangy488@jnu.edu.cn.

Förderung

  • Guangdong Provincial Natural Science Foundation
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Program key projects

Zitieren

APA

Chen, Q., Zhang, Q., He, L., Yang, M., Wang, H., Lin, M., Li, B., Chen, G., Wang, Y., Chen, T., & Shuai, X. (2025). T-cell hitchhiking nanodrug activates the cGAS-STING signaling pathway for enhanced cancer immunotherapy. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.10.044

Vancouver

Chen Q, Zhang Q, He L, Yang M, Wang H, Lin M, et al. T-cell hitchhiking nanodrug activates the cGAS-STING signaling pathway for enhanced cancer immunotherapy. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.10.044

BibTeX
@article{Chen2025,
  author = {Chen, Qi and Zhang, Qiaoyun and He, Lizhen and Yang, Meijin and Wang, Heting and Lin, Minzhao and Li, Bo and Chen, Gengjia and Wang, Yong and Chen, Tianfeng and Shuai, Xintao},
  title = {T-cell hitchhiking nanodrug activates the cGAS-STING signaling pathway for enhanced cancer immunotherapy},
  journal = {Acta Biomaterialia},
  year = {2025},
  doi = {10.1016/j.actbio.2025.10.044}
}
Kostenlos starten →